

Literatur zum Beitrag von Martin Plöderl, Seite 22

- Amendola, S., Plöderl, M., & Hengartner, M. P. (2021). Did the introduction and increased prescribing of antidepressants lead to changes in long-term trends of suicide rates? *European Journal of Public Health*, 31(2), 291–297. <https://doi.org/10.1093/eurpub/ckaa204>
- Cipriani, A., Hawton, K., Stockton, S., & Geddes, J. R. (2013). Lithium in the prevention of suicide in mood disorders: Updated systematic review and meta-analysis. *BMJ*, 346, f3646. <https://doi.org/10.1136/bmj.f3646>
- Forte, A., Pompili, M., Imbastro, B., De Luca, G. P., Mastrangelo, M., Montalbani, B., & Baldessarini, R. J. (2021). Effects on suicidal risk: Comparison of clozapine to other newer medicines indicated to treat schizophrenia or bipolar disorder. *Journal of Psychopharmacology*, 35(9), 1074–1080. <https://doi.org/10.1177/02698811211029738>
- Healy, D., & Aldred, G. (2005). Antidepressant drug use & the risk of suicide. *International Review of Psychiatry*, 17(3), 163–172. <https://doi.org/10.1080/09540260500071624>
- Hengartner, M. P., Amendola, S., Kaminski, J. A., Kindler, S., Bschor, T., & Plöderl, M. (2021). Suicide risk with selective serotonin reuptake inhibitors and other new-generation antidepressants in adults: A systematic review and meta-analysis of observational studies. *Journal of Epidemiology and Community Health*, 75, 523–530. <https://doi.org/10.1136/jech-2020-214611>
- Hengartner, M. P., & Plöderl, M. (2019a). Newer-generation antidepressants and suicide risk in randomized controlled trials: A re-analysis of the FDA database. *Psychotherapy and Psychosomatics*, 88(4), 247–248. <https://doi.org/10.1159/000501215>
- Hengartner, M. P., & Plöderl, M. (2019b). Reply to the letter to the editor: „Newer-generation antidepressants and suicide Risk: Thoughts on Hengartner and Plöderl's re-analysis“. *Psychotherapy and Psychosomatics*, 88(6), 373–374. <https://doi.org/10.1159/000502485>
- Hetrick, S. E., McKenzie, J. E., Bailey, A. P., Sharma, V., Moller, C. I., Badcock, P. B., Cox, G. R., Merry, S. N., & Meader, N. (2021). New generation antidepressants for depression in children and adolescents: A network meta-analysis. *Cochrane Database of Systematic Reviews*, 2021(5). <https://doi.org/10.1002/14651858.CD013674.pub2>
- Högberg, G., Antonuccio, D. O., & Healy, D. (2015). Suicidal risk from TADS study was higher than it first appeared. *The International Journal of Risk & Safety in Medicine*, 27(2), 85–91. <https://doi.org/10.3233/JRS-150645>
- Högberg, G. N., & Bremberg, S. G. (2018). Antidepressant medication might increase the risk of self-harm injuries: Findings in 17 OECD countries. *European Journal of Public Health*. <https://doi.org/10.1093/eurpub/cky268>
- Katz, I. R., Rogers, M. P., Lew, R., Thwin, S. S., Doros, G., Ahearn, E., Ostacher, M. J., DeLisi, L. E., Smith, E. G., Ringer, R. J., Ferguson, R., Hoffman, B., Kaufman, J. S., Paik, J. M., Conrad, C. H., Holmberg, E. F., Boney, T. Y., Huang, G. D., Liang, M. H., ... Yurgelun-Todd, D. (2022). Lithium treatment in the prevention of repeat suicide-related outcomes in veterans with major depression or bipolar disorder: A randomized clinical trial. *JAMA Psychiatry*, 79(1), 24. <https://doi.org/10.1001/jamapsychiatry.2021.3170>
- Le Noury, J., Nardo, J. M., Healy, D., Jureidini, J., Raven, M., Tufanaru, C., & Abi-Jaoude, E. (2015). Restoring Study 329: Efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence. *BMJ*, h4320. <https://doi.org/10.1136/bmj.h4320>
- Lewitzka, U., Severus, E., Bauer, R., Ritter, P., Müller-Oerlinghausen, B., & Bauer, M. (2015). The suicide prevention effect of lithium: More than 20 years of evidence—a narrative review. *International Journal of Bipolar Disorders*, 3(1), 15. <https://doi.org/10.1186/s40345-015-0032-2>
- Meltzer, H. Y. (2003). Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). *Archives of General Psychiatry*, 60(1), 82. <https://doi.org/10.1001/archpsyc.60.1.82>
- Moncrieff, J., Plöderl, M., Nabi, Z., Stansfeld, J., & Wood, L. (2022). Evidence does not confirm that lithium prevents suicide: A reply to Bschor et al. *Epidemiology and Psychiatric Sciences*, 31, e88. <https://doi.org/10.1017/S2045796022000737>
- Nabi, Z., Stansfeld, J., Plöderl, M., Wood, L., & Moncrieff, J. (2022). Effects of lithium on suicide and suicidal behaviour: A systematic review and meta-analysis of randomised trials. *Epidemiology and Psychiatric Sciences*, 31, e65. <https://doi.org/10.1017/S204579602200049X>
- Plöderl, M. (2019). Antidepressiva in der Suizidprävention. Eine kritische Bestandsaufnahme. *Suizidprophylaxe*, 46(2), 53–64.
- Plöderl, M., Amendola, S., & Hengartner, M. P. (subm.). Observational studies of antidepressant use and suicide risk are selectively published in psychiatric journals. <https://osf.io/avhg4/>
- Plöderl, M., Hengartner, M. P., Bschor, T., & Kaminski, J. A. (2020). Commentary to „antidepressants and suicidality: A re-analysis of the re-analysis“. *Journal of Affective Disorders*, 273, 252–253. <https://doi.org/10.1016/j.jad.2020.04.025>
- Plöderl, M., Hengartner, M. P., & Volkmann, C. (2022). Suizidpräventive Effekte von Ketamin und Esketamin. *Nervenheilkunde*, 41(04), 240–245. <https://doi.org/10.1055/a-1761-3192>
- Plöderl, M., & Volkmann, C. (2021). Esketamin. Ein berechtigter Hype in der Suizidprävention? *Suizidprophylaxe*, 48, 10–14.
- Schneider-Thoma, J., Efthimiou, O., Huhn, M., Krause, M., Reichelt, L., Röder, H., Davis, J. M., Salanti, G., & Leucht, S. (2018). Second-generation antipsychotic drugs and short-term mortality: A systematic review and meta-analysis of placebo-controlled randomised controlled trials. *The Lancet Psychiatry*, 5(8), 653–663. [https://doi.org/10.1016/S2215-0366\(18\)30177-9](https://doi.org/10.1016/S2215-0366(18)30177-9)
- Sharma, T., Guski, L. S., Freund, N., & Gøtzsche, P. C. (2016). Suicidality and aggression during antidepressant treatment: Systematic review and meta-analyses based on clinical study reports. *BMJ*. <https://doi.org/10.1136/bmj.i65>
- Stone, M. B., Laughren, T. P., Jones, M. L., Levenson, M., Holland, P. C., Hughes, A., Hammad, T. A., Temple, R., & Rochester, G. (2009). Risk of suicidality in clinical trials of antidepressants in adults: Analysis of proprietary data submitted to US Food and Drug Administration. *BMJ*, 339, 1–10. <https://doi.org/10.1136/bmj.b2880>